Key result
Non-vitamin K antagonist oral anticoagulants were reviewed for their efficacy and safety compared to warfarin in patients with atrial fibrillation and diabetes mellitus.
Why the study?
Do non-vitamin K antagonist oral anticoagulants improve efficacy and safety compared to warfarin in patients with atrial fibrillation and diabetes mellitus?
Do non-vitamin K antagonist oral anticoagulants improve efficacy and safety compared to warfarin in patients with atrial fibrillation and diabetes mellitus?
Answers are grounded in this paper and cite their sources.
This is a commentary discussing the efficacy and safety of NOACs versus warfarin in patients with atrial fibrillation and diabetes mellitus.
"Comments on efficacy and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and diabetes mellitus." Acta Cardiologica, 76(9), p. 1041
No takes yet. Share an insight, caveat, or question.
Murat et al. (2021) studied this question. Non-vitamin K antagonist oral anticoagulants were reviewed for their efficacy and safety compared to warfarin in patients with atrial fibrillation and diabetes mellitus.
Synapse has enriched 10 related papers. Consider them for comparative context: